7,935 results match your criteria: "The Lancet. Infectious diseases[Journal]"
Lancet Infect Dis
December 2024
MMV Medicines for Malaria Venture, Geneva, Switzerland.
Background: Novel antimalarials are needed to address emerging resistance to artemisinin and partner drugs. We did two trials to evaluate safety, tolerability, pharmacokinetics, and activity against blood stage Plasmodium falciparum for the drug candidate MMV533.
Methods: A phase 1a first-in-human (FIH) trial was conducted at Nucleus Network (Melbourne, VIC, Australia).
Lancet Infect Dis
December 2024
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. Electronic address:
Background: Diarrhoeal diseases claim more than 1 million lives annually and are a leading cause of death in children younger than 5 years. Comprehensive global estimates of the diarrhoeal disease burden for specific age groups of children younger than 5 years are scarce, and the burden in children older than 5 years and in adults is also understudied. We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to assess the burden of, and trends in, diarrhoeal diseases overall and attributable to 13 pathogens, as well as the contributions of associated risk factors, in children and adults in 204 countries and territories from 1990 to 2021.
View Article and Find Full Text PDFLancet Infect Dis
December 2024
Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicical and Health Ciences, Tel Aviv University, Tel Aviv 6139001, Israel.
Lancet Infect Dis
December 2024
Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Mahosot Hospital, Vientiane, Laos; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address:
Antimicrobial resistance (AMR) is predicted to outstrip malaria, HIV, and tuberculosis combined as the leading infectious cause of death by 2050. Strengthening the knowledge and evidence base for AMR with surveillance and research is one of the five main objectives of the WHO Global Action Plan on AMR. While recent efforts to strengthen diagnosis and surveillance have been encouraging, these are unlikely to be sustainable without continued funding support in most low-resource settings.
View Article and Find Full Text PDFLancet Infect Dis
December 2024
College of Medicine-Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
Lancet Infect Dis
December 2024
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages.
Methods: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%.
Lancet Infect Dis
December 2024
INSERM, IAME, U1137, Team DeSCID, Paris, France; Assistance Publique Hôpitaux de Paris, Medical and Infectious Diseases ICU, Bichat Hospital, F75018 Paris, France; OUTCOME REA Research Group, Drancy, France. Electronic address:
Background: Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce. Pharmacokinetic and pharmacodynamic differences between the agents might affect clinical response rates. We aimed to compare the effectiveness of ceftolozane-tazobactam and ceftazidime-avibactam for treatment of invasive multidrug-resistant P aeruginosa infections.
View Article and Find Full Text PDFLancet Infect Dis
December 2024
Pandemic Sciences Institute, Oxford, UK.
The west Africa Ebola disease epidemic (2014-16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure in many ways-a slow, cumbersome, and disjointed effort by a global architecture that was not fit for purpose for a rapidly spreading outbreak. In the most affected countries, health-care workers and other responders felt helpless-dealing with an overwhelming number of patients but with few, if any, tools at their disposal to provide high-quality care.
View Article and Find Full Text PDFLancet Infect Dis
December 2024
Pandemic Sciences Institute, Oxford, UK.
A key lesson from the west Africa (2014-16) Ebola disease epidemic was that outbreak responses fail when they respond to patients through a narrow clinical lens without considering the broader community and social context of care. Here, in the second of two Series papers on the modern landscape of Ebola disease, we review progress made in the last decade to improve patient-centred care. Although the biosafety imperatives of treating Ebola disease remain, recent advances show how to mitigate these so that patients are cared for in a safe and dignified manner that encourages early treatment-seeking behaviour and provides support after the return of patients to their communities.
View Article and Find Full Text PDFLancet Infect Dis
December 2024
Genetics, Vaccines and Infectious Diseases Research Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Department of Forensic Science, Pathological Anatomy, Gynaecology and Obstetrics and Paediatrics, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago, 15701 Santiago de Compostela, Galicia, Spain. Electronic address:
Lancet Infect Dis
December 2024
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. Electronic address:
Lancet Infect Dis
December 2024
Department of Biochemistry and Kavli Institute for Nanoscience Discovery and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Electronic address:
Background: Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for Plasmodium falciparum malaria. However, neither induces blood-stage immunity against parasites that break through from the liver. RH5.
View Article and Find Full Text PDFLancet Infect Dis
December 2024
Department of Malaria Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Lancet Infect Dis
December 2024
National Institute for Infectious Diseases Lazzaro Spallanzani, Rome 00149, Italy.
Lancet Infect Dis
December 2024
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. Electronic address:
Lancet Infect Dis
December 2024
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 98109, Seattle, WA, USA. Electronic address:
Lancet Infect Dis
November 2024
Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, 01221-020 São Paulo, Brazil.
Lancet Infect Dis
November 2024
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address:
Tuberculosis remains a public health concern, and electronic monitors show promise in improving treatment adherence and health outcomes among patients with tuberculosis. This Review aims to provide a comprehensive understanding of the implementation barriers and facilitators of electronic monitors for patients with tuberculosis, by use of an implementation science framework. A literature search was done across Ovid MEDLINE, CINAHL, Embase, Cochrane Library, Web of Science, and Global Health databases from their inception to April 25, 2024.
View Article and Find Full Text PDF